51420-32-7 Usage
General Description
1-(4,5-dihydro-1H-imidazol-2-yl)hydrazine, also known simply as imidazolyl hydrazine, is a chemical compound with the molecular formula C3H8N4. It is a hydrazine derivative with an imidazolyl group, making it an important building block in the synthesis of various pharmaceutical and agrochemical compounds. Imidazolyl hydrazine has been investigated for its potential use in the treatment of cancer, as well as its role as a precursor in the production of fungicides and insecticides. It is also used in research as a versatile intermediate for the synthesis of a variety of nitrogen-containing compounds. However, due to its toxic and potentially hazardous nature, proper safety precautions and handling procedures should be followed when working with 1-(4,5-dihydro-1H-imidazol-2-yl)hydrazine.
Check Digit Verification of cas no
The CAS Registry Mumber 51420-32-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,4,2 and 0 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 51420-32:
(7*5)+(6*1)+(5*4)+(4*2)+(3*0)+(2*3)+(1*2)=77
77 % 10 = 7
So 51420-32-7 is a valid CAS Registry Number.
InChI:InChI=1/C3H8N4/c4-7-3-5-1-2-6-3/h1-2,4H2,(H2,5,6,7)
51420-32-7Relevant articles and documents
Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
Alexandre-Moreira, Magna S.,Aquino, Pedro G. V.,Bourguignon, Jean-Jacques,Bri-Card, Jacques,Freitas, Johnnatan D.,Meneghetti, Mario R.,Nascimento, Igor J. S.,Queiroz, Aline C.,Rodrigues, Klinger A. F.,Rodrigues, Raiza R. L.,Santos, Mariana S.,Schmitt, Martine,de Aquino, Thiago M.,Araújo, Morgana V.,Fran?a, Paulo H. B.,Rodrigues, érica E. E. S.,Santos-Júnior, Paulo F. S.,da Silva-Júnior, Edeildo F.,de Araújo-Júnior, Jo?o X.
, p. 151 - 169 (2022/02/05)
Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li
